Sumitomo Mitsui Trust Holdings Inc. Cuts Stock Holdings in DaVita Inc. (NYSE:DVA)

Sumitomo Mitsui Trust Holdings Inc. lessened its holdings in DaVita Inc. (NYSE:DVA) by 1.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 132,694 shares of the company’s stock after selling 2,225 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned about 0.15% of DaVita worth $13,901,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. State of Michigan Retirement System boosted its position in DaVita by 0.6% during the 4th quarter. State of Michigan Retirement System now owns 15,939 shares of the company’s stock valued at $1,670,000 after acquiring an additional 100 shares in the last quarter. Treasurer of the State of North Carolina boosted its position in DaVita by 0.5% during the third quarter. Treasurer of the State of North Carolina now owns 24,503 shares of the company’s stock valued at $2,316,000 after purchasing an additional 123 shares in the last quarter. Daiwa Securities Group Inc. grew its stake in DaVita by 3.2% in the third quarter. Daiwa Securities Group Inc. now owns 4,631 shares of the company’s stock valued at $438,000 after purchasing an additional 144 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in DaVita by 1.0% in the third quarter. PNC Financial Services Group Inc. now owns 15,088 shares of the company’s stock worth $1,426,000 after purchasing an additional 153 shares in the last quarter. Finally, New Mexico Educational Retirement Board lifted its position in shares of DaVita by 7.4% during the third quarter. New Mexico Educational Retirement Board now owns 2,886 shares of the company’s stock valued at $273,000 after buying an additional 200 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors.

Insider Transactions at DaVita

In related news, insider James O. Hearty sold 26,164 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $119.64, for a total value of $3,130,260.96. Following the completion of the transaction, the insider now directly owns 20,264 shares in the company, valued at approximately $2,424,384.96. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, insider James O. Hearty sold 26,164 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $119.64, for a total value of $3,130,260.96. Following the completion of the sale, the insider now directly owns 20,264 shares in the company, valued at $2,424,384.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Javier Rodriguez sold 67,603 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $126.11, for a total value of $8,525,414.33. Following the transaction, the chief executive officer now directly owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The disclosure for this sale can be found here. Insiders have sold 134,540 shares of company stock worth $16,551,071 over the last quarter. 1.40% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have weighed in on DVA. TheStreet upgraded shares of DaVita from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. Barclays assumed coverage on DaVita in a research report on Wednesday, March 6th. They set an “equal weight” rating and a $133.00 target price on the stock. UBS Group lifted their target price on shares of DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a research note on Wednesday, February 14th. Truist Financial lifted their price objective on shares of DaVita from $130.00 to $135.00 and gave the stock a “hold” rating in a research note on Tuesday, February 20th. Finally, StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 16th. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, DaVita presently has a consensus rating of “Moderate Buy” and an average target price of $118.50.

DaVita Stock Performance

DVA opened at $132.52 on Tuesday. The firm has a 50 day moving average of $131.04 and a two-hundred day moving average of $109.53. The firm has a market capitalization of $11.62 billion, a PE ratio of 17.91, a P/E/G ratio of 1.14 and a beta of 1.04. The company has a current ratio of 1.19, a quick ratio of 1.13 and a debt-to-equity ratio of 6.65. DaVita Inc. has a 12-month low of $71.51 and a 12-month high of $141.54.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, February 13th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.53 by $0.34. The firm had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.01 billion. DaVita had a net margin of 5.70% and a return on equity of 64.42%. The firm’s revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the company posted $1.11 earnings per share. On average, analysts anticipate that DaVita Inc. will post 9.23 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.